Glioma of Brain Clinical Trial
Official title:
Glioma Microenvironment an Exploratory Study
Diffuse glioms are primary brain tumors characterized by infiltrative growth and high heterogeneity, which render the disease mostly incurable. Advances in genetic analysis revealed that molecular and epigenetic alterations predict patients´s overall survival and clinical outcome. However, glioma tumorigenicity is not exclusively caused by its genetic alterations. The crosstalk between tumor cells and the surrounding microenvironment plays a crucial role in modulating glioma growth and aggressiveness. In this sense, to understand the tumor microenvironment would elucidate potential treatment alternatives. The focus will be to evaluate myeloid cells and cytokines levels.
The proposal is to study gene expression and early epigenetic changes in myeloid cells from brain tumors and co-culture experiments. Tough RNA-seq, ATAC-seg and subsequent analysis to monitor the differential gene expression through different time points followed by stimuli. The study will compare the obtained results with sequencing data from microglia of full-fledged human tumor samples (glioblastoma and low grade gliomas). Additionally it will evaluated the immunologic characteristic of the tumor through cytokines levels analysis (TNF-α, IL-4, IL-6, IL-8, IL-10, IL-13, IFN-γ, TGF-β e IL-1ra). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03796507 -
Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation
|
Early Phase 1 | |
| Withdrawn |
NCT04406610 -
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03665545 -
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03194906 -
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03739372 -
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
|
N/A | |
| Completed |
NCT03779230 -
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03728673 -
A Study Utilizing Escitalopram in Glioma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03496181 -
Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
|
||
| Recruiting |
NCT03180697 -
The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas
|
N/A | |
| Recruiting |
NCT03949192 -
Efficacy of Kangliuwan for Recurrent Grade IV Glioma
|
||
| Terminated |
NCT03927274 -
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
|
Early Phase 1 | |
| Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03763396 -
Azoles Targeting Recurrent High Grade Gliomas
|
Early Phase 1 | |
| Terminated |
NCT03698201 -
Blood Biomarker Signature in Glioma
|
||
| Terminated |
NCT03436433 -
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
|
Phase 2 | |
| Recruiting |
NCT03750890 -
Visual Study of Molecular Genotype in Glioma Evolution
|
||
| Enrolling by invitation |
NCT03102112 -
Noninvasively Predicting Gene Status of Glioma
|
N/A | |
| Recruiting |
NCT03935685 -
Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
|
Phase 2 | |
| Completed |
NCT03834740 -
A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
|
Early Phase 1 | |
| Recruiting |
NCT03849430 -
Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients
|